Venigalla S, et al. - In this retrospective cohort study utilizing the National Cancer Database, researchers assessed the trends, patterns of use, and effectiveness of adjuvant endocrine therapy among men with hormone receptor (HR)-positive breast cancer. Males at least 18 years old with nonmetastatic HR-positive invasive breast cancer who underwent surgery with or without adjuvant endocrine therapy were included in the primary study cohort. The same inclusion criteria were used to identify a cohort of female patients for comparative analyses by sex. Although the use of adjuvant endocrine therapy was shown to be associated with improved overall survival, a sex disparate underuse of adjuvant endocrine therapy was found among men with HR-positive breast cancer.